CLINICAL PROTOCOL 
Product VCL-1102 
July 7, 1994 
VICAL INC. 
9373 Towne Centre Dr., Ste. 100 
San Diego, CA 92121 
4.2 Exclusion Criteria 
4.2.1 Patients who are Hepatitis B antigen positive, HIV 
antibody positive or IL-2 antibody positive. 
4.2.2 Patients with a history of autoimmune disease. 
4.2.3 Patients with a history of Hepatitis (acute or chronic 
active). 
4.2.4 Patients with any active infection requiring parenteral 
antibiotics. 
4.2.5 Patients with uncontrolled hypertension or New York 
Heart Association stage 3 or 4 disease. 
4.2.6 Patients receiving radiation, chemotherapy, steroid 
therapy within the past 3 weeks or 6 weeks if they have 
received BCNU or Mitomycin C. 
4.2.7 Patients receiving concurrent anticancer drug therapy, any 
immunosuppressive drugs and any other experimental 
therapy. 
4.2.8 Patients who fail to meet the criteria for immunocompetence 
as defined in 4.1.11 above. 
4.2.9 Patients with diabetes mellitus who are not controlled by 
medical treatment. 
4.3.0 Patients with uncontrolled brain metastases. 
4.3.1 Patients with pre-diagnosed psychiatric disorders that 
would make compliance to the protocol difficult, or 
would compromise ability to give informed consent. 
5.0 STUDY DRUG 
The study drug (VCL-1102) will be supplied as three sterile vials containing (i) 
Interleukin-2 plasmid DNA, (ii) DMRIE/DOPE lipid mixture and (iii) normal saline. 
All components will be stable for at least eight weeks under recommended storage 
[608] 
Recombinant DNA Research, Volume 20 
